Loading
Acute Myeloid Leukemia Research / Immunodeficiency and Autoimmune Disorders · Journal article
Molecular Cancer · August 7, 2026
Encouraging direction, but not yet definitive.
This preclinical study uses CRISPR screens to identify MCT1-driven metabolic reprogramming as a resistance mechanism to SMAD3 inhibition in cancer cells. Pharmacological and genetic MCT1 inhibition synergizes with SMAD3 blockade to reduce tumor viability in vitro and tumor growth in vivo across multiple cancer models, suggesting a rationale for clinical combination therapy.
Preclinical mechanistic study using genome-wide CRISPR activation and knockout screens with in vivo tumor models. Cancer cell lines (BRAF-mutated melanoma, KRAS-mutated lung adenocarcinoma, BRAF inhibitor-resistant cells) and mouse melanoma models. Intervention: SMAD3 inhibition combined with pharmacological or genetic MCT1 inhibition. Compared with: SMAD3 inhibition alone; MCT1 inhibition alone.
MCT1, a lactate transporter, mediates cancer cell escape from SMAD3 inhibition through metabolic reprogramming MCT1 inhibition synergizes strongly with SMAD3 blockade to impair tumor viability in BRAF-mutated melanoma Co-inhibition of SMAD3 and MCT1 potently reduces tumor growth in vivo in preclinical models
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This identifies MCT1 as a therapeutic target to overcome resistance to SMAD3 inhibitors and provides mechanistic rationale for combination therapy. However, translation to clinical benefit requires validation in human trials, as preclinical synergy does not guarantee clinical efficacy.
Well-designed mechanistic study with CRISPR screens and in vivo validation identifies MCT1 as a resistance mechanism to SMAD3 inhibition and demonstrates synergy in preclinical models, but lacks clinical evidence and human efficacy data.
As stated by the source record.
This identifies MCT1 as a therapeutic target to overcome resistance to SMAD3 inhibitors and provides mechanistic rationale for combination therapy. However, translation to clinical benefit requires validation in human trials, as preclinical synergy does not guarantee clinical efficacy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Resistance to therapy remains a critical challenge in cancer. This is exemplified by TGF-β pathway inhibitors which, despite broad clinical testing, have failed to deliver survival benefit. More precise SMAD3 targeting has shown preclinical promise, yet resistance mechanisms to SMAD3 inhibition remain entirely unknown. Using complementary genome-wide CRISPR activation and knockout screens, we discover that cancer cells escape SMAD3 inhibition through metabolic reprogramming. Strikingly, this escape is driven not by transcriptional bypass but by the lactate transporter MCT1, with the effect preserved across BRAF-mutated melanoma, KRAS-mutated lung adenocarcinoma, and mouse melanoma. Mechanistically, SMAD3 inhibition creates energetic stress that cancer cells exploit through MCT1. By conferring metabolic flexibility and switching toward glycolysis under drug pressure, MCT1 increases anabolic activity to drive lipid and cholesterol synthesis. Pharmacological and genetic MCT1 inhibition synergizes strongly with SMAD3 blockade to impair tumor viability in BRAF-mutated melanoma, while suppressing drug-tolerant cell emergence in BRAF inhibitor-resistant cells. Critically, this synergy extends to preclinical models, where co-inhibition of SMAD3 and MCT1 potently reduces tumor growth in vivo. Given the additional and well-established role of MCT1 in shaping the tumor immune microenvironment via lactate transport, these results position MCT1 as both a metabolic and immunological target and provide a strong rationale for the repurposing of TGF-β/SMAD3 pathway inhibitors in combination.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.